Business, energy, technology, markets and global industry news from Business News Today

datopotamab deruxtecan

PharmaDeviceNews datopotamab deruxtecan
CHMP backs Datroway in first-line TNBC
Pharma & Biotech

Datroway nears EU first-line approval for metastatic triple-negative breast cancer

Discover how Datroway’s EU recommendation could reshape first-line treatment for metastatic triple-negative breast cancer. Read the analysis.

Read More
Representative image: A cancer patient receives infusion-based oncology care in a modern clinic, reflecting Datroway’s FDA approval as a new first-line treatment option for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy.
Pharma & Biotech

AstraZeneca and Daiichi Sankyo deepen ADC ambitions with Datroway’s TNBC approval

Datroway challenges chemotherapy in first-line TNBC. AstraZeneca and Daiichi Sankyo now face the real test: adoption, safety and access.

Read More